| NCT ID | NCT01166009 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Center for International Blood and Marrow Transplant Research |
| Condition | Autologous Stem Cell Transplantation |
| Study Type | OBSERVATIONAL |
| Enrollment | 99,999,999 participants |
| Start Date | 2002-07 |
| Primary Completion | 2050-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 99,999,999 participants in total. It began in 2002-07 with a primary completion date of 2050-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies. A secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries. Objectives: To learn more about what makes stem cell transplants and cellular therapies work well such as: * Determine how well recipients recover from their transplants or cellular therapy; * Determine how recovery after a transplant or cellular therapy can be improved; * Determine how a donor's or recipient's genetics impact recipient recovery after a transplant or cellular therapy; * Determine how access to transplant or cellular therapy for different groups of patients can be improved; * Determine how well donors recover from the collection procedures.
Eligibility Criteria
Eligibility to Participate in the Research Database Recipient Eligibility Criteria: * Any recipient of an unrelated or related donor or autologous HSC transplant in a CIBMTR center is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Individual with Marrow Toxic Injury Eligibility Criteria: * Any individual who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Transplant Network (RITN) is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Eligible individuals may have received supportive care only, growth factor support, HSC transplant or other appropriate medical treatment for marrow toxic injury. Treatments applied are at the discretion of the care facility, and are not determined by the NMDP or CIBMTR. Unrelated Donor Eligibility Criteria: * All donors registered on the NMDP Registry who have been requested to donate a product for a recipient are eligible to participate in the Research Database. * All maternal cord blood donors are enrolled in the NMDP Cord Blood Bank Investigational New Drug (IND) protocol, and sign an informed consent document specific to that protocol. Data collected as part of the Cord Blood Bank protocol are included in the Research Database.
Contact & Investigator
Patricia Steinert, PhD, MBA
PRINCIPAL INVESTIGATOR
Center for International Blood and Marrow Transplant Research
Frequently Asked Questions
Who can join the NCT01166009 clinical trial?
This trial is open to participants of all sexes, studying Autologous Stem Cell Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01166009 currently recruiting?
Yes, NCT01166009 is actively recruiting participants. Contact the research team at databaseIRB@nmdp.org for enrollment information.
Where is the NCT01166009 trial being conducted?
This trial is being conducted at Minneapolis, United States, Milwaukee, United States.
Who is sponsoring the NCT01166009 clinical trial?
NCT01166009 is sponsored by Center for International Blood and Marrow Transplant Research. The principal investigator is Patricia Steinert, PhD, MBA at Center for International Blood and Marrow Transplant Research. The trial plans to enroll 99,999,999 participants.